



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 48/00 (2006.01)
A61K 31/712 (2006.01) A61P 21/00 (2006.01)
A61K 31/7125 (2006.01) C12N 15/113 (2010.01)
A61K 47/68 (2017.01)

(21) International Application Number:

PCT/US2024/061427

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/614,024 22 December 2023 (22.12.2023) US

(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
1560 Trapelo Road, Waltham, MA 02451 (US).

(72) Inventors: **WEEDEN, Timothy**; 1560 Trapelo Road, Waltham, MA 02451 (US). **HSIA, Nelson**; 1560 Trapelo Road, Waltham, MA 02451 (US). **ZANOTTI, Stefano**; 1560 Trapelo Road, Waltham, MA 02451 (US). **BESKROVNAYA, Oxana**; 1560 Trapelo Road, Waltham, MA 02451 (US). **QIU, Qifeng**; 1560 Trapelo Road, Waltham, MA 02451 (US). **HILDERBRAND, Scott**; 1560 Trapelo Road, Waltham, MA 02451 (US). **DECKERT, Jochen**; Hans-Sachs-Strasse 34c, 95444 Bayreuth (DE). **VORNLOCHER, Hans-peter**; c/o AxoLabs GmbH, Fritz-Homshuch-Str.9, 95326 Kulmbach (DE). **HOSSBACH, Markus**; Dr. Martin Luther Str. 15, 95326 Kulmbach (DE). **HULTSCH, Kathrin**; c/o AxoLabs GmbH, Fritz-Homshuch-Str.9, 95326 Kulmbach (DE). **YODER, Nicholas C.**; 1560 Trapelo Road, Waltham, MA 02451 (US).

VIEIRA, Benjamin; 1560 Trapelo Road, Waltham, MA 02451 (US).

(74) Agent: **DAWSON, Cara B.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY




FIG. 1

(57) Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., an RNAi oligonucleotide such as an siRNA, useful for targeting DUX4) covalently linked to an antibody (e.g., anti-TfR1 antibody).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*